{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T10:01:30Z","timestamp":1775728890787,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Rigel Pharmaceuticals Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12325-026-03522-6","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T08:28:44Z","timestamp":1772267324000},"page":"1802-1815","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed\/Refractory Acute Myeloid Leukemia"],"prefix":"10.1007","volume":"43","author":[{"given":"Justin M.","family":"Watts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian A.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence R.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie E.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Cope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2430-0350","authenticated-orcid":false,"given":"Amber","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"de Botton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"issue":"11","key":"3522_CR1","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","volume":"361","author":"ER Mardis","year":"2009","unstructured":"Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058\u201366.","journal-title":"N Engl J Med"},{"issue":"8","key":"3522_CR2","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/ajh.24072","volume":"90","author":"CD DiNardo","year":"2015","unstructured":"DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732\u20136.","journal-title":"Am J Hematol"},{"key":"3522_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14123012","author":"M Messina","year":"2022","unstructured":"Messina M, Piciocchi A, Ottone T, Paolini S, Papayannidis C, Lessi F, et al. Prevalence and prognostic role of IDH mutations in acute myeloid keukemia: results of the GIMEMA AML1516 protocol. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14123012.","journal-title":"Cancers (Basel)"},{"key":"3522_CR4","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Acute Myeloid Leukemia V.2.2025. \u00ae National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed [April 7, 2025]. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"issue":"4","key":"3522_CR5","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1021\/acs.jmedchem.9b01423","volume":"63","author":"JA Caravella","year":"2020","unstructured":"Caravella JA, Lin J, Diebold RB, Campbell A-M, Ericsson A, Gustafson G, et al. Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor. J Med Chem. 2020;63(4):1612\u201323.","journal-title":"J Med Chem"},{"issue":"4","key":"3522_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","volume":"9","author":"J Popovici-Muller","year":"2018","unstructured":"Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, et al. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018;9(4):300\u20135.","journal-title":"ACS Med Chem Lett"},{"issue":"11","key":"3522_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s11864-024-01264-7","volume":"25","author":"JM Watts","year":"2024","unstructured":"Watts JM, Shaw SJ, Jonas BA. Looking beyond the surface: olutasidenib and ivosidenib for treatment of mIDH1 acute myeloid leukemia. Curr Treat Options Oncol. 2024;25(11):1345\u201353.","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"3522_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1084\/jem.20092506","volume":"207","author":"S Gross","year":"2010","unstructured":"Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207(2):339\u201344.","journal-title":"J Exp Med"},{"key":"3522_CR9","unstructured":"Food and Drug Administration. Highlights of prescribing information: REZLIDHIA (olutasidenib). Revised 12\/2022. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed Apr 7 2025."},{"key":"3522_CR10","unstructured":"Food and Drug Administration. Highlights of prescribing information: TIBSOVO (ivosidenib). Revised 10\/2023. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed 7 Apr 2025."},{"issue":"13","key":"3522_CR11","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","volume":"7","author":"S de Botton","year":"2023","unstructured":"de Botton S, Fenaux P, Yee K, Recher C, Wei AH, Montesinos P, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023;7(13):3117\u201327.","journal-title":"Blood Adv"},{"issue":"25","key":"3522_CR12","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386\u201398.","journal-title":"N Engl J Med"},{"issue":"16","key":"3522_CR13","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1182\/bloodadvances.2023009854","volume":"7","author":"S Venugopal","year":"2023","unstructured":"Venugopal S, Watts J. Olutasidenib: from bench to bedside. Blood Adv. 2023;7(16):4358\u201365.","journal-title":"Blood Adv"},{"key":"3522_CR14","unstructured":"Center for Drug Evaluation and Research. NDA Multidisciplinary Review and Evaluation. NDA 211192. Tibsovo (ivosidenib). 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/211192Orig1s000MultidisciplineR.pdf. Accessed 8 Apr 2025."},{"key":"3522_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"issue":"18","key":"3522_CR16","doi-asserted-by":"publisher","first-page":"6336","DOI":"10.1002\/cam4.4182","volume":"10","author":"S de Botton","year":"2021","unstructured":"de Botton S, Brandwein JM, Wei AH, Pigneux A, Quesnel B, Thomas X, et al. Improved survival with enasidenib versus standard of care in relapsed\/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. Cancer Med. 2021;10(18):6336\u201343.","journal-title":"Cancer Med"},{"key":"3522_CR17","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submission to NICE. 2016."},{"issue":"2","key":"3522_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311.","journal-title":"Med Decis Making"},{"issue":"22","key":"3522_CR19","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","volume":"32","author":"H Uno","year":"2014","unstructured":"Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014;32(22):2380\u20135.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3522_CR20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/jrsm.1718","volume":"15","author":"S Ren","year":"2024","unstructured":"Ren S, Ren S, Welton NJ, Strong M. Advancing unanchored simulated treatment comparisons: a novel implementation and simulation study. Res Synth Methods. 2024;15(4):657\u201370.","journal-title":"Res Synth Methods"},{"issue":"9","key":"3522_CR21","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","volume":"4","author":"S Choe","year":"2020","unstructured":"Choe S, Wang H, DiNardo CD, Stein EM, de Botton S, Roboz GJ, et al. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020;4(9):1894\u2013905.","journal-title":"Blood Adv"},{"key":"3522_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-020-00161-7","volume":"9","author":"J Yu","year":"2020","unstructured":"Yu J, Li Y, Zhang D, Wan D, Jiang Z. Clinical implications of recurrent gene mutations in acute myeloid leukemia. Exp Hematol Oncol. 2020;9:4.","journal-title":"Exp Hematol Oncol"},{"key":"3522_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000611","author":"B Kiesewetter","year":"2020","unstructured":"Kiesewetter B, Cherny NI, Boissel N, Cerisoli F, Dafni U, de Vries EGE, et al. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open. 2020. https:\/\/doi.org\/10.1136\/esmoopen-2019-000611.","journal-title":"ESMO Open"},{"issue":"3","key":"3522_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1017\/S0266462319000333","volume":"35","author":"DM Phillippo","year":"2019","unstructured":"Phillippo DM, Dias S, Elsada A, Ades AE, Welton NJ. Population adjustment methods for indirect comparisons: a review of National Institute for Health and Care Excellence technology appraisals. Int J Technol Assess Health Care. 2019;35(3):221\u20138.","journal-title":"Int J Technol Assess Health Care"},{"key":"3522_CR25","unstructured":"Food and Drug Administration. Highlights of prescribing information: VENCLEXTA (venetoclax). Revised 6\/2022. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed 23 Apr 2025."},{"issue":"3","key":"3522_CR26","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3324\/haematol.2020.252569","volume":"106","author":"A Maiti","year":"2021","unstructured":"Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021;106(3):894\u20138.","journal-title":"Haematologica"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03522-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03522-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03522-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:13:55Z","timestamp":1775726035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03522-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3522"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03522-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aaron Sheppard and Amber Thomassen are employees of Rigel Pharmaceuticals Inc. Florence R. Wilson and Julie E. Park are employees of Precision AQ. Shannon Cope was an employee of Precision AQ at the time the research took place and is now an employee of Unpuzzle Health Economics and Outcomes Research Ltd. Precision AQ, funded by Rigel Pharmaceuticals Inc., performed all analyses and provided professional editorial assistance. Justin M. Watts reports consulting or advisory board roles for BMS, Servier, Rigel, Daiichi Sankyo, Aptose, and Ativarre, research funding from Takeda, Rigel, and Immune Systems Key, Ltd, and is a member of DMC for Rafael Pharma and Reven Pharma. Eunice Wang reports consulting or advisory board roles for J&J, Kite, AmgenStemline, Sumitomo Pharma, Takeda, Pfizer, Rigel, GlaxoSmithKline, Daiichi Sankyo, Blueprint, Jazz, Astellas, Novartis, Gilead, BMS, and Abbvie. Brian A. Jonas reports consulting or advisory board roles for AbbVie, BMS, Daiichi Sankyo, Gilead, Kura, Rigel, Schrodinger, Syndax, and Treadwell, participation in the data monitoring committee for Gilead, and research funding to his institution from AbbVie, Amgen, Aptose, AROG, Biomea, BMS, Celgene, Forma, Forty-Seven, Genentech\/Roche, Gilead, GlycoMimetics, Hanmi, Immune-Onc, Jazz, Kymera, Loxo, Pfizer, Pharmacyclics, and Treadwell. St\u00e9phane de Botton reports consulting or advisory board roles for Servier, BMS, GSK, Syndax Pharmaceuticals, Remix Therapeutics, Rigel, Jazz Pharmaceuticals, Astellas, and AbbVie, and research funding from Forma Therapeutics, Auron Therapeutics, BMS, AbbVie, Servier, Jazz Pharmaceuticals, Astellas, and Loxo Oncology. Jorge E. Cortes reports consulting or advisory board roles for Pfizer, Sun Pharma, Syndax, Nerviano, Lilly, Biopath Holdings, Novartis, and Rigel, and research funding from Sun Pharma, AbbVie, Ascentage, and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Results presented in this article are based on a retrospective analysis of data from published studies, and therefore no institutional board review was required. Review boards at participating institutions approved all procedures for the 2102-HEM-101 and AG120-C-001 trials.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}